<DOC>
	<DOCNO>NCT00330967</DOCNO>
	<brief_summary>The Objectives study : ( 1 ) compare inflammatory response insulin resistance skeletal muscle systemic infusion lipid local infusion lipid femoral artery . would cause minimal systemic hyperlipidemia local plasma free fatty acid ( FFA ) concentration similar systemic lipid infusion , ( 2 ) determine inflammatory response insulin resistance skeletal muscle infusion lipid femoral artery describe NF-KB inhibition high dose salicylate treatment human .</brief_summary>
	<brief_title>Mechanisms Insulin Resistance Humans</brief_title>
	<detailed_description>Insulin resistance skeletal muscle characteristic abnormality obesity metabolic syndrome major factor responsible development type 2 diabetes . Although mechanisms responsible muscle insulin resistance largely unclear , lipid oversupply important factor . Among numerous potential mechanism whereby lipid oversupply may cause muscle insulin resistance , current evidence point towards inflammation critical . Recent study animal , however , indicate inflammatory response skeletal muscle may require presence circulate pro-inflammatory factor suggest inflammation induce insulin resistance skeletal muscle may secondary event . More specifically , activation Nuclear Factor-Kappa B ( NF-kB ) , inflammatory master switch drive production numerous pro-inflammatory cytokine fat liver , implicate cause insulin resistance skeletal muscle increase circulate pro-inflammatory cytokine . In contrast , animal study find activation NF-KB directly skeletal muscle little effect insulin sensitivity produce abnormality increase proteasome activity . The study shall therefore undertaken determine extent lipid-induced inflammation insulin resistance skeletal muscle require presence circulate proinflammatory factor human .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>two group 16 healthy subject diabetes impaired glucose tolerance peripheral vascular disease pulmonary disease clinically significant hepatic renal disease triglyceride &gt; 200mg/dl anemia abnormal PT , PTT INR pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Fat Emulsions , Intravenous</keyword>
	<keyword>Free Fatty Acids</keyword>
	<keyword>Glucose Clamp Technique</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Insulin Resistance</keyword>
	<keyword>Muscle , Skeletal</keyword>
	<keyword>NF-Kappa B</keyword>
</DOC>